131548
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 10
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -5.430713998
- umap2_2d
- 1.143139792
- umap1_3d
- -0.412311317
- umap2_3d
- 2.904359173
- umap3_3d
- 0.222831037
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.430
- ANDROGEN_RESPONSE+0.410
- INFLAMMATORY_RESPONSE+0.400
- PROTEIN_SECRETION+0.400
- INTERFERON_GAMMA_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.350
- ESTROGEN_RESPONSE_EARLY+0.330
- COMPLEMENT+0.310
- TNFA_SIGNALING_VIA_NFKB+0.290
- ESTROGEN_RESPONSE_LATE+0.280
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.450
- E2F_TARGETS-0.380
- NOTCH_SIGNALING-0.360
- G2M_CHECKPOINT-0.340
- HEDGEHOG_SIGNALING-0.310
- SPERMATOGENESIS-0.290
- ANGIOGENESIS-0.240
- PANCREAS_BETA_CELLS-0.240
- UV_RESPONSE_UP-0.170
- DNA_REPAIR-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 110682 | EPN | Supratentorial EPN | 0.792 |
| 2 | SRR1346813 | GTEX | — | 0.778 |
| 3 | TCGA-44-2656-01A-02R-0946-07 | — | cohortA1 | 0.774 |
| 4 | BS_10APZRVT | Meningioma | — | 0.773 |
| 5 | SRR1321853 | GTEX | — | 0.759 |
| 6 | BS_S2TA8R29 | high-grade glioma | — | 0.753 |
| 7 | SRR8613769 | — | F | 0.752 |
| 8 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.752 |
| 9 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.749 |
| 10 | BS_5AF6ZNJF | Meningioma | — | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |